CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNSP CNS Pharmaceuticals, Inc.

Closed Good Friday 04-17 16:00:00 EDT

0.8200

-0.0001

-0.01%

盘后0.8148

-0.0052-0.63%

19:52 EDT

High0.8600	Low0.7715	Vol173.47K
Open0.8200	D1 Closing0.8201	Amplitude10.79%
Mkt Cap2.41M	Tradable Cap2.40M	Total Shares2.94M
T/O141.80K	T/O Rate5.94%	Tradable Shares2.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CNSP","market":"US","secType":"STK","nameCN":"CNS Pharmaceuticals, Inc.","latestPrice":0.82,"timestamp":1744920000000,"preClose":0.8201,"halted":0,"volume":173467,"hourTrading":{"tag":"盘后","latestPrice":0.8148,"preClose":0.82,"latestTime":"19:52 EDT","volume":1487,"amount":1226.973566,"timestamp":1744933947832},"delay":0,"floatShares":2922198,"shares":2944381,"eps":-38.870243,"marketStatus":"Closed Good Friday","change":-0.0001,"latestTime":"04-17 16:00:00 EDT","open":0.82,"high":0.86,"low":0.771525,"amount":141798.6042795,"amplitude":0.107883,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-38.870243,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1573189200000,"exchange":"NASDAQ","adjPreClose":0.8201,"preHourTrading":{"tag":"盘前","latestPrice":0.86,"preClose":0.8201,"latestTime":"09:06 EDT","volume":2895,"amount":2547.1282308,"timestamp":1744895169257},"postHourTrading":{"tag":"盘后","latestPrice":0.8148,"preClose":0.82,"latestTime":"19:52 EDT","volume":1487,"amount":1226.973566,"timestamp":1744933947832},"volumeRatio":0.6094495939545774},"requestUrl":"/m/hq/s/CNSP","defaultTab":"news","newsList":[{"id":"2524494594","title":"CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2524494594","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524494594?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:46","pubTimestamp":1743597995,"startTime":"0","endTime":"0","summary":"Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.Make smarter investments with  weekly expert stock picks from the Smart Investor Newsletter.Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts. Biotech Alert: Searches spiking for these stocks today. CNS Pharmaceuticals down 55% after Berubicin doesn’t show OS superiority in GBM. Morning Movers: Mobileye jumps following Volkswagen ADAS partnership","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-fy24-eps-124635719.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-fy24-eps-124635719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNSP","CNS"],"gpt_icon":0},{"id":"2524115923","title":"CNS Pharmaceuticals Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524115923","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524115923?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:05","pubTimestamp":1743509100,"startTime":"0","endTime":"0","summary":"Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme  for treatment of brain malignancies. CNS Pharmaceuticals plans to engage the FDA and obtain feedback on the design of a study potentially focused on the registration of TPI 287 in recurrent GBM in 2025.The Company recently reported results from the primary analysis of Berubicin in second line treatment of glioblastoma multiforme . The trial compared Berubicin to Lomustine, a current standard of care in GBM. The analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint. However, although the trial was","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-full-2024-120500175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4097","CNS","CNSP","PFS","OS","BK4195","BK4211","BK4135"],"gpt_icon":0},{"id":"2524168269","title":"CNS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524168269","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524168269?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 16:34","pubTimestamp":1743496497,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryCNS Pharmaceuticals Inc CNSP.OQ reported a quarterly adjusted loss of $9.25 per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nL5N3QF0GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP"],"gpt_icon":0},{"id":"2522009524","title":"CNS Pharmaceuticals Inc  expected to post a loss of $9.66 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522009524","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522009524?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:02","pubTimestamp":1743159728,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc  expected to post a loss of $9.66 a share - Earnings Preview CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to report resultson March 31 (estimated) for the period ending D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB0OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP"],"gpt_icon":0},{"id":"2522890778","title":"CNS Pharmaceuticals announces primary analysis of berubicin in GBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2522890778","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522890778?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:36","pubTimestamp":1742927809,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) announced the primary analysis of its clinical trial evaluating Berubicin, the first anthracycline demonstrated to exten...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-announces-primary-analysis-of-berubicin-in-gbm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-announces-primary-analysis-of-berubicin-in-gbm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNSP","CNS","BK4135"],"gpt_icon":0},{"id":"2522889320","title":"CNS Pharmaceuticals Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2522889320","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522889320?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:26","pubTimestamp":1742927160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNSP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 14:26 ET (18:26 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4135","CNS","BK4007"],"gpt_icon":0},{"id":"2522075290","title":"CNS Pharma Shares Sink After Berubicin Trial for Brain Cancer Misses Survival Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075290","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075290?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:49","pubTimestamp":1742906940,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, leading to a selloff of its shares.The biopharmaceutical company said Tuesday that superiority in overall survival had been the primary endpoint of the trial for Berubicin, though the treatment still shows a favorable safety profile. An analysis of the trial's outcomes is still ongoing, CNS said.Shares fell 55% to $1.52 in premarket trading.The trial was comparing Berubicin to Lomustine, which is the current standard of care in recurrent or progressive Glioblastoma Multiforme.CNS said the trial data shows overall survival is comparable between the two treatments, including for patients with the most unfavorable tumor markers.\"We are awaiting long-term follow-up of patients still alive as well as those still on trial, and will evaluate our substantial clinical dataset to obtain additional insight","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007","BK4135","CNS"],"gpt_icon":0},{"id":"2522676022","title":"CNS Pharmaceuticals - Berubicin Showed Clinically Relevant Outcomes Comparable to Lomustine Across Multiple Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2522676022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522676022?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:03","pubTimestamp":1742904190,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q818P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2522283022","title":"CNS Pharmaceuticals Inc: Berubicin Did Not Show a Statistically Significant Difference in Overall Survival, the Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2522283022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522283022?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:03","pubTimestamp":1742904190,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q818P:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2522022609","title":"CNS Pharmaceuticals Inc -Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022609","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022609?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:03","pubTimestamp":1742904190,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q818P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2522022405","title":"CNS Pharmaceuticals-Continues Development of Novel Taxane, TPI 287, With Published Clinical Efficacy Data in Glioblastoma Multiforme","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022405?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:03","pubTimestamp":1742904190,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q818P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2522242000","title":"CNS Pharmaceuticals Shares Halted for News Pending Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2522242000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522242000?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:57","pubTimestamp":1742903849,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL3N3Q80R3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2521115490","title":"CNS Pharmaceuticals Inc - Pursuant to Sales Agreement, Increases Sales Price of Shares to $43.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2521115490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521115490?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 06:30","pubTimestamp":1742509837,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q318M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2514855342","title":"CNS Pharmaceuticals reports cash position of $14M as of February 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2514855342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514855342?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 22:20","pubTimestamp":1740579650,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) provided an update on its current cash position and discussed the completion of its recent initiative to maintain its li...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-reports-cash-position-of-14m-as-of-february-26?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-reports-cash-position-of-14m-as-of-february-26?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNSP","CNS","BK4007","BK4135"],"gpt_icon":0},{"id":"2514530508","title":"CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2514530508","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514530508?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 22:05","pubTimestamp":1740578700,"startTime":"0","endTime":"0","summary":"Cash on hand provides over one year of runway to fund expected operations. HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided an update on its current cash position and discussed the completion of its recent initiative to maintain its listing on the NASDAQ Capital Market .The Company's lead drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme , an aggressive and currently incurable form of brain cancer. The Company expects to release primary analysis data on Berubicin's performance in this designed-to-be pivo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-provides-current-cash-140500098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","QLD","CNS","NVIW.SI","LU2095319765.USD","USJW.SI","MNQmain","IE00B3QW5Z07.USD","NQmain","BK4588","BK4007","TQQQ","BK4112","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","TSYW.SI","NDAQ","QID","IE00BKPKM429.USD","IE00BGHQF748.EUR","USAW.SI","PSQ","CNSP","BK4135",".IXIC"],"gpt_icon":1},{"id":"2512702438","title":"S&P 500 Edges Higher; Analog Devices Earnings Top Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2512702438","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512702438?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 02:29","pubTimestamp":1739989753,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43821314/s-analog-devices-earnings-top-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKLA","SPY","SEDG","SINT","COMP","NKLAQ","CNSP","VOO","ALUR",".SPX","ADI"],"gpt_icon":1},{"id":"2512107486","title":"CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2512107486","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512107486?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 23:27","pubTimestamp":1739978832,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals  said Wednesday it will implement a 1-for-50 reverse stock split to raise the company's per-share trading price and ensure compliance with Nasdaq's minimum share price listing requirement.The company said its common stock will start trading on a split-adjusted basis on Nasdaq on Friday.Shares of CNS Pharmaceuticals fell over 33% in recent trading.Price: 0.10, Change: -0.05, Percent Change: -33.33","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NQmain","BK4135","CNSP","CNS"],"gpt_icon":1},{"id":"2512102442","title":"CNS Pharmaceuticals announces 1-for-50 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2512102442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512102442?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 21:40","pubTimestamp":1739972408,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) announced a 1-for-50 reverse split of its common stock. Beginning on February 21, 2025, the Company’s common stock will ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-announces-1-for-50-reverse-stock-split-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-announces-1-for-50-reverse-stock-split-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNSP","CNS","BK4135"],"gpt_icon":0},{"id":"2512854166","title":"CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2512854166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512854166?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 22:35","pubTimestamp":1739889315,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part of t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-to-present-at-glioblastoma-drug-development-summit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-to-present-at-glioblastoma-drug-development-summit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFSS8Q28.SGD","LU0964807845.USD","SMMF","LU1551013342.USD","IE0004445239.USD","IE0004445015.USD","LU0417517546.SGD","BK4533","LU1814569148.SGD","LU0096362180.USD","IE00BN29S564.USD","LU1153585028.USD","LU0971096721.USD","LU2023250330.USD","MA","CNSP","LU0942090050.USD","LU2720916845.USD","LU2417539215.USD","BK4007","LU1670627923.USD","LU0820561909.HKD","LU0256863811.USD","IE00BFSS7M15.SGD","IE00BQXX3F31.USD","LU2552382132.HKD","LU1718418525.SGD","LU0238689110.USD","LU0820562030.AUD","BK4211","BK4535","LU0198837287.USD","LU0689472784.USD","IE00B775H168.HKD","LU1852331112.SGD","LU0957791311.USD","BK4559","LU0345770308.USD","LU2764263203.CNY","LU0061474705.USD","LU1989764664.SGD","LU0786609619.USD","LU0823421416.USD","LU0345769631.USD","CNS","LU0276348264.USD","LU1261432733.SGD","LU0109392836.USD","LU2764262908.HKD","LU1691799644.USD"],"gpt_icon":0},{"id":"2505562658","title":"CNS Pharmaceuticals Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2505562658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505562658?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 20:04","pubTimestamp":1737720261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nFWN3OK16P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cnspharma.com","stockEarnings":[{"period":"1week","weight":-0.3051},{"period":"1month","weight":-0.769},{"period":"3month","weight":-0.8391},{"period":"6month","weight":-0.8656},{"period":"1year","weight":-0.9984},{"period":"ytd","weight":-0.8638}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.196826},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.081635},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.208333},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.01799},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002034},{"month":6,"riseRate":0.4,"avgChangeRate":-0.170886},{"month":7,"riseRate":0.2,"avgChangeRate":-0.250938},{"month":8,"riseRate":0.4,"avgChangeRate":-0.098088},{"month":9,"riseRate":0,"avgChangeRate":-0.21514},{"month":10,"riseRate":0.2,"avgChangeRate":0.089289},{"month":11,"riseRate":0.6,"avgChangeRate":-0.043335},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.19069}],"exchange":"NASDAQ","name":"CNS Pharmaceuticals, Inc.","nameEN":"CNS Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CNS Pharmaceuticals, Inc.,CNSP,CNS Pharmaceuticals, Inc.股票,CNS Pharmaceuticals, Inc.股票老虎,CNS Pharmaceuticals, Inc.股票老虎国际,CNS Pharmaceuticals, Inc.行情,CNS Pharmaceuticals, Inc.股票行情,CNS Pharmaceuticals, Inc.股价,CNS Pharmaceuticals, Inc.股市,CNS Pharmaceuticals, Inc.股票价格,CNS Pharmaceuticals, Inc.股票交易,CNS Pharmaceuticals, Inc.股票购买,CNS Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction